Australia's most trusted
source of pharma news
Wednesday, 10 December 2025
Posted 9 December 2025 AM
Pfizer's latest round of cost-cutting has hit Australia with undisclosed job losses as part of the company restructure.
Earlier this year, Pfizer announced further belt-tightening, unveiling extra savings of US$1.2 billion. It was the third time the company's cost realignment program had been revised, boosting the total reduction in spending by the end of 2027 to US$5.7 billion.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.